DPA treatment has been shown to be associated with an increased risk of autoimmune diseases other than MG or lupus, such as glomerulonephritis, Goodpasture syndrome, vasculitis, polymyositis, ulcerative colitis, multiple sclerosis, polyarthritis, psoriasis, serpiginosa perforans, pemphigus, pemphigoid, and epidermolysis bullosa [65]
Recent advances in nanotechnology have yielded multifunctional platforms incorporating GSH-responsive linkages, redox-active metals, and prodrug designs with strong promise for targeted delivery and theranostics
The influence of UA levels on the progression of oxidative stress and neuroinflammation at different stages of neurodegenerative diseases requires further investigation
They have different mechanisms and different evidence bases
The supportive argument may be that BPC 157 by itself induces NO-release (demonstrated from gastric mucosa supernatant), like L-arginine, but also in conditions where L-arginine is not working [14]